FDA approves new daily GLP-1 pill and how it compares to Wegovy tablets

The FDA approved Eli Lilly’s oral GLP-1 pill Foundayo (orforglipron), which showed about 12.4% average weight loss in trials and can be taken any time with or without food; it differs from Wegovy in formulation and dosing requirements.

The FDA has approved a second oral GLP-1 medication, Foundayo (orforglipron) from Eli Lilly, adding to the recently released Wegovy tablet. Foundayo is a small-molecule GLP-1 rather than a peptide, and company results reported an average weight loss of about 12.4% at the highest dose in trials. The company and outside clinicians have highlighted differences in how the pill is taken and in trial outcomes compared with existing GLP-1 options. The approval is discussed alongside trial safety notes and comments from clinicians and Lilly executives about broader availability. Key details: - The approved drug is orforglipron, marketed as Foundayo by Eli Lilly. - In company clinical trial data, the highest Foundayo dose produced an average 12.4% weight loss (about 27.3 pounds) versus 0.9% (about 2.2 pounds) with placebo. - Foundayo is a synthetic small molecule and can be taken any time of day with or without food, unlike the Wegovy (oral semaglutide) pill, which has specific morning and fasting instructions tied to an absorption enhancer. - Lilly reported trial reductions in measures like waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure; a head-to-head trial in people with type 2 diabetes reportedly favored Foundayo over oral semaglutide on key metrics. - Safety warnings reported for Foundayo mirror other GLP-1s and include possible thyroid tumors/cancer risk, pancreatitis, gastrointestinal effects, dehydration, and potential interference with oral birth control. Summary: The approval of Foundayo adds another oral GLP-1 option and may broaden choices for patients who prefer non-injectable therapies or need more flexible dosing than some existing pills require. Lilly has said it aims for broad global distribution, while timing and specific access details are undetermined at this time.